Multiple Myeloma

Most recent

Improved Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

A majority of patients with multiple myeloma (MM) relapse after therapy, and the duration of remission decreases with each line of therapy.1 Novel agents, including proteasome inhibitors (PIs) and immunomodulatory agents (IMIDs), have improved outcomes for patients...

Other

Dr. Richard LeBlanc: Impressive Results from POLLUX Trial

The addition of daratumumab to lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) alone was evaluated in the POLLUX trial, a randomized, open-label, multicentre, phase III study. The population of the study included 569 patients with multiple...

Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for R/R MM among patients with 1–3 prior lines of therapy based on previous treatment exposure: Updated analysis of POLLUX

Moreau P, et al. ASH 2016:489 Background In a phase I/II study, 32 patients with relapsed or refractory (R/R) multiple myeloma (MM) were treated with daratumumab, lenalidomide, and dexamethasone (DRd), which induced rapid, deep, and durable responses with a manageable...

Twitter feed

RT @NatureNews: In the age of immunotherapy, cancer biologists are relying on a new generation of tools to learn how the interplay between…
h J R
Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R